Location History:
- Füllinsdorf, CH (2012)
- Heidelberg, DE (2011 - 2013)
- Basel, CH (2014)
Company Filing History:
Years Active: 2011-2014
Title: Holger Deppe - Innovator in Pharmaceutical Chemistry
Introduction
Holger Deppe, an accomplished inventor based in Heidelberg, Germany, has made significant contributions to the field of pharmaceutical chemistry. With a total of five patents to his name, his innovative work focuses on the development of compounds that have the potential to treat serious medical conditions.
Latest Patents
Among Holger's latest inventions are novel, substituted 3-arylamino pyridine derivatives. These compounds possess unique properties that make them valuable as MEK inhibitors. The invention details pharmaceutically acceptable salts, solvates, and prodrug compounds, which are instrumental in treating hyperproliferative diseases such as cancer, restenosis, and inflammation. Furthermore, the applications of these compounds extend to their use in mammalian and human treatment, supported by pharmaceutical compositions containing them.
Career Highlights
Holger has had a remarkable career, working with esteemed companies in the pharmaceutical sector. Notably, he has held positions at Merck Serono S.A. and Santhera Pharmaceuticals (Schweiz) AG. His work in these organizations has not only advanced his expertise but has also contributed to significant advancements in drug development and innovation.
Collaborations
Throughout his career, Holger Deppe has collaborated with talented professionals in the field. Colleagues such as Ulrich Abel and Achim Feurer have worked alongside him, fostering a collaborative environment that enhances creativity and innovation in pharmaceutical research.
Conclusion
Holger Deppe's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his commitment to addressing critical health challenges. His work, particularly in developing 3-arylamino pyridine derivatives, represents a significant step forward in the fight against various hyperproliferative diseases. As research progresses, Holger’s inventions may lead to new therapeutic solutions and improve patient outcomes.